MedPath

Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis

Not Applicable
Conditions
In-stent Restenosis
CHD - Coronary Heart Disease
Percutaneous Coronary Intervention
Interventions
Procedure: Percutaneous Coronary Intervention under Angiography
Procedure: Percutaneous Coronary Intervention under OCT
Registration Number
NCT03809754
Lead Sponsor
Chinese PLA General Hospital
Brief Summary

This study is a prospective, registry trial aimed to compare the clinical and angiographic outcomes of OCT-guided and angiography-guided PCI in patients with coronary DES-ISR.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
240
Inclusion Criteria
  • Age 18 years or older
  • Patients with angina or evidence of myocardial ischaemia
  • Patients with restenotic lesions in a previously DES area of a coronary artery
  • Patients suitable to receive any types of percutaneous coronary intervention (including balloon angioplasty and stent implantation)
  • The stent diameter of DES-ISR is 2.5mm to 4.0mm
  • Target lesion length < 30mm
  • Target lesion stenosis ≥ 70% diameter stenosis on visual assessment, or ≥ 50% diameter stenosis and with evidence of myocardial ischaemia ischemic
Exclusion Criteria
  • Patients with acute myocardial infarction with 1 week
  • Patients with evidence of extensive thrombosis in the target vessel
  • Patients with left main coronary artery disease
  • Patients with cardiogenic shock, left ventricular ejection fraction < 40%,significant renal dysfunction and severe heart valve disease
  • Patients who had cerebral stroke within 6 months before PCI
  • Patients with a life expectancy < 1 year
  • Patients not able to adhere to follow-up visits

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Angiography-guided PCIPercutaneous Coronary Intervention under Angiography-
OCT-guided PCIPercutaneous Coronary Intervention under OCT-
Primary Outcome Measures
NameTimeMethod
In-segment late loss at 9 months follow-up9 months
Secondary Outcome Measures
NameTimeMethod
Rate of 9-month binary restenosis9 months
Rate of myocardial infarction12 months
Rates of acute success1 month
Rate of major adverse cardiovascular events12 months
Number of participants with all-cause death12 months
Number of Participants with target lesion failure (TLF)12 months

Trial Locations

Locations (1)

Yundai Chen

🇨🇳

Beijing, China

© Copyright 2025. All Rights Reserved by MedPath